Acyclovir

• Description:

  Acyclovir (Aciclovir) is a potent, orally active antiviral agent. Acyclovir has antiherpetic activity with IC50 values of 0.85 μM and 0.86 μM for HSV-1 and HSV-2, respectively. Acyclovir induces cell cycle perturbation and apoptosis. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia[1][2][3][4].

• Product Name Alternative:

  Aciclovir; Acycloguanosine

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Antibiotic; Apoptosis; Bacterial; HSV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Apoptosis

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/Acyclovir.html

• Concentration:

  10mM

• Purity:

  99.34

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  O=C1NC (N) =NC2=C1N=CN2COCCO

• Molecular Formula:

  C8H11N5O3

• Molecular Weight:

  225.21

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Benedetti S, et, al. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity. Life Sci. 2018 Dec 15;215:80-85.|[2]Suzuki M, et, al. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72 (2) :157-61.|[3]Li Z, et, al. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus. Antivir Chem Chemother. 1999 Sep;10 (5) :251-7.|[4]Lönnqvist B, et, al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer. 1993 May;1 (3) :139-44.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  HSV-1; HSV-2

• CAS Number:

  59277-89-3